ReShape Lifesciences Inc. (RSLS)
| Market Cap | 32.68M |
| Revenue (ttm) | 11.30M |
| Net Income (ttm) | -21.63M |
| Shares Out | 6.93M |
| EPS (ttm) | -3.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $4.52 |
| Previous Close | $5.29 |
| Change ($) | -0.77 |
| Change (%) | -14.56% |
| Day's Open | 4.15 |
| Day's Range | 4.15 - 4.52 |
| Day's Volume | 506 |
| 52-Week Range | 1.51 - 11.50 |
SAN CLEMENTE, CA / ACCESSWIRE / March 10, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the fourth quarter an...
Webinar to discuss results on March 10, 2021 at 4:30 p.m. E.T SAN CLEMENTE, CA / ACCESSWIRE / March 8, 2021 / ReShape Lifesciences Inc. (OTCQB:RSLS), a leading developer and distributor of minimally inv...
ReShape Lifesciences' (RSLS) CEO Bart Bandy on Q3 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q2 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc. (RSLS) CEO Bart Bandy on Q1 2019 Results - Earnings Call Transcript
ReShape Lifesciences Inc.'s (RSLS) CEO Dan Gladney on Q4 2018 Results - Earnings Call Transcript
About RSLS
ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomac... [Read more...]
| Industry Medical Devices | IPO Date Nov 15, 2007 |
| CEO Barton Bandy | Employees 37 |
| Stock Exchange OTCMKTS | Ticker Symbol RSLS |
Financial Performance
In 2020, RSLS's revenue was $11.30 million, a decrease of -25.12% compared to the previous year's $15.09 million. Losses were -$21.63 million, -70.85% less than in 2019.